Pharmacologic management of the opioid neonatal abstinence syndrome.
Publication/Presentation Date
10-1-2012
Abstract
Opioid use in pregnant women has increased over the last decade. Following birth, infants with in utero exposure demonstrate signs and symptoms of withdrawal known as the neonatal abstinence syndrome (NAS). Infants express a spectrum of disease, with most requiring the administration of pharmacologic therapy to ensure proper growth and development. Treatment often involves prolonged hospitalization. There is a general lack of high-quality clinical trial data to guide optimal therapy, and significant heterogeneity in treatment approaches. Emerging trends in the treatment of infants with NAS include the use of sublingual buprenorphine, transition to outpatient therapy, and pharmacogenetic risk stratification.
Volume
59
Issue
5
First Page
1147
Last Page
1165
ISSN
1557-8240
Published In/Presented At
Kraft, W. K., & van den Anker, J. N. (2012). Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatric clinics of North America, 59(5), 1147–1165. https://doi.org/10.1016/j.pcl.2012.07.006
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
23036249
Department(s)
Administration and Leadership
Document Type
Article